Antares Pharma Announces Termination Of LEO Pharma Marketing Agreement

(RTTNews) - Antares Pharma, Inc. (ATRS) announced that it has regained U.S. marketing rights to OTREXUP (methotrexate) injection for subcutaneous use for the psoriasis indication through the termination of an exclusive promotion and marketing agreement with LEO Pharma A/S for detailing OTREXUP to dermatologists for symptomatic control of severe recalcitrant psoriasis in adults.

"While we are disappointed in the psoriasis market penetration to date, we believe there is still an opportunity to establish OTREXUP as an important treatment option for patients with psoriasis, and we will evaluate all of our options, including looking for a new partner, to market OTREXUP to dermatologists," said Eamonn Hobbs, President and CEO of Antares Pharma.